Back to EUR-Lex homepage

EUR-Lex Access to European Union law

Back to EUR-Lex homepage

This document is an excerpt from the EUR-Lex website

Use quotation marks to search for an "exact phrase". Append an asterisk (*) to a search term to find variations of it (transp*, 32019R*). Use a question mark (?) instead of a single character in your search term to find variations of it (ca?e finds case, cane, care).
Search tips
Need more search options? Use the Advanced search
You are here

Document 62017CN0443

Case C-443/17: Reference for a preliminary ruling from High Court of Justice (Chancery Division) (United Kingdom) made on 24 July 2017 — Abraxis Bioscience LLC v Comptroller General of Patents

OJ C 309, 18.9.2017, p. 30–31 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

18.9.2017   

EN

Official Journal of the European Union

C 309/30

Reference for a preliminary ruling from High Court of Justice (Chancery Division) (United Kingdom) made on 24 July 2017 — Abraxis Bioscience LLC v Comptroller General of Patents

(Case C-443/17)

(2017/C 309/41)

Language of the case: English

Referring court

High Court of Justice (Chancery Division)

Parties to the main proceedings

Applicant: Abraxis Bioscience LLC

Defendant: Comptroller General of Patents

Question referred

Is Article 3(d) of the SPC Regulation (1) to be interpreted as permitting the grant of an SPC where the marketing authorisation referred to in Article 3(b) is the first authorisation within the scope of the basic patent to place the product on the market as a medicinal product and where the product is a new formulation of an old active ingredient?

(1)  Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products (OJ L 152, p. 1)

Top